Fast Track Immunotherapeutic Development with MuScreen™


"CrownBio brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing problems in oncology, cardiovascular, and metabolic disease.

Leveraging our industry expertise, CrownBio's global resources help customers answer the most challenging questions about human biology. We begin with the end insight to help you achieve your goals"

Dr Jean-Pierre Wery
CEO, Crown Bioscience Inc.

High Throughput Syngeneic In Vivo Screen for Evaluating Immunotherapies

Now Available: MuScreen PD Mode - Enroll by 8th October 2018

Limited Availability! 6 Model MuScreen Efficacy Mode Enrollment ends 1st November 2018

  • Evaluate TGI with the Syngeneic Efficacy Screening Panel of 6 or 12 models

  • Evaluate PD effects (FACS analysis of TIL/TAM) with the Syngeneic PD Screening Panel of 12 or 6 models

  • Large-scale, staggered screening reduces variability from sources such as antibodies and mice

  • Improve efficiency and save study time by rapidly identifying markers or models

  • An effective and accurate way to find the right model - particularly for your combination studies

  • Benefit from multiple clients sharing the results of vehicle and other common groups significantly reducing both the number of animals needed and your associated costs

Figure 1: Syngeneic Efficacy Screening Panel Study Design


Figure 2: Syngeneic PD Screening Panel Study Design

Choose MuScreen Over a Traditional In Vitro Study

  • Comprising of a predesignated syngeneic panel across a range of cancer types, built upon our collection of validated and well-characterized syngeneic models

  • You can leverage detailed model checkpoint inhibitor benchmarking data, as well as RNAseq and optional FACS analysis information

  • Models run on a large scale, preset schedule, with shared vehicle and common groups to improve efficiency, reproducibility, and cost-effectiveness

Request MuScreen Pricing